Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: A selected review

Annals of Nuclear Medicine

Volumn 25, Issue 2, 2011, Pages 75-85

  Nisa, Lutfun ^a,b   Savelli, Giordano ^a   Giubbini, Raffaele ^a  

^a Medicina Nucleare   (Italy)

^b Center for Nuclear Medicine and Ultrasound   (Bangladesh)

Author keywords

90Y DOTATOC; Gastroenteropancreatic NET; Neuroendocrine tumors; Peptide receptor radionuclide therapy; Somatostatin analog

Indexed keywords

DOTA TYR3 OCTREOTIDE YTTRIUM 90; MORPHINE; RADIOISOTOPE; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG;

ANEMIA; ASTHENIA; BLOOD TOXICITY; BONE METASTASIS; CARCINOID SYNDROME; DIARRHEA; DYSPNEA; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GASTROINTESTINAL TUMOR; HOT FLUSH; HUMAN; LIVER METASTASIS; LIVER TOXICITY; LYMPHOCYTOPENIA; MYELOBLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PAIN; PANCYTOPENIA; PARESTHESIA; PELLAGRA; PRIORITY JOURNAL; RADIATION DOSE; RADIOISOTOPE THERAPY; REVIEW; SOMATOSTATIN RELEASE; SOMATOSTATINOMA; STOMACH DISTENSION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VOMITING; WEAKNESS; WHEEZING;

CLINICAL TRIALS AS TOPIC; DIGESTIVE SYSTEM NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEUROENDOCRINE TUMORS; OCTREOTIDE; RECEPTORS, SOMATOSTATIN;

EID: 79954439894     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-010-0444-0     Document Type: Review

References (48)

1. Kaltsas GA, Papadogias D, Makras P, Grossman AB. Treatment of advanced neuroendocrine tumors with radiolabelled somatostatin analogues. Endocr Relat Cancer. 2005;12:683-9.
2. Khanna G, Bushnell D, O'Dorisio MS. Utility of radiolabelled somatostatin receptor analogues for staging/restaging and treatment of somatostatin receptor-positive pediatric tumors. Oncologist. 2008;13:382-9. (Pubitemid 351679917)
3. Ö berg K. Management of neuroendocrine tumors. Ann Oncol. 2004;15:iv293-8.
4. Bieligk S, Jaffe BM. Islet cell tumors of the pancreas. Surg Clin North Am. 1995;75:1025-40.
5. Ö berg K. Advances in chemotherapy and biotherapy of endocrine tumors. Curr Opin Oncol. 1998;10:58-65. (Pubitemid 28039243)
6. Higgins GA, Recant L, Fischman AB. The glucagonoma: surgically curable diabetes. Am J Surg. 1979;137:142-8.
7. Prinz RA, Dorsch TR, Lawrence AM. Clinical aspects of glucagons producing islet cell tumors. Am J Gastroenterol. 1981; 76:125-31. (Pubitemid 12234879)
8. Raut C, Kulke M, Glickman J, Swanson RS, Ashley SW. Carcinoid tumors. Curr Probl Surg. 2006;43:383-450.
9. De Herder WW, Hofland LJ, Van Der Lely AJ, Lambert SW. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2003;10:451-8. (Pubitemid 38094881)
10. De Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabelled peptides for tumor therapy: current status and future directions. Eur J Nucl Med. 2003;30:463-9. (Pubitemid 36692876)
11. McCarthy KE, Woltering EA, Antony LB. In situ radiotherapy with 111In-pentreotide State of the art and perspectives. Q J Nucl Med. 2000;44:88-95.
12. Antony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium 111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002; 32:123-32. (Pubitemid 34311078)
13. Béhé M, Heppeler A, Maecke HR. New somatostatin analogs for SPET and PET. Eur J Nucl Med 1996;23:1144 (abstract).
14. Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumors. Acta Oncol. 2007;46:723-34. (Pubitemid 47123757)
15. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJM, Kooij PPM, de Herder WW, et al. Treatment of patients with gastroenteropancreatic (GEP) tumors with the novel radiolabelled somatostatin analogue [177LuDOTA(0), Tyr(3) octreotide. Eur J Nucl Med Mol Imaging. 2003;30:417-22. (Pubitemid 36692868)
16. Otte A, Jermann E, Béhé M, Goetze M, Bucher HC, Roser HW, et al. DOTATOC: A powerful new tool for receptor mediated radionuclide therapy. Eur J Nucl Med. 1997;24:792-6.
17. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Ytterium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 1998;351:417-8.
18. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATAC first clinical results. Eur J Nucl Med. 1999;26:1439-47. (Pubitemid 29515605)
19. Paganelli G, Zoboli S, Cremonesi M, Mäcke HR, Chinol M. Receptor-mediated radionuclide therapy with 90Y-DOTA-DPhe1- Tyr3-Octreotide: preliminary report in cancer patients. Cancer Biother Radiopharm. 1999;14:477-83. (Pubitemid 30029795)
20. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumors: a clinical phase II study. Ann Oncol. 2001;12:941-5. (Pubitemid 32725766)
21. Waldherr C, Schumacher T, Maecke HR, Schirp U, Forrer F, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med. 2002;43:610-6. (Pubitemid 34507110)
22. Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, et al. Receptor mediated radiotherapy with 90Y-DOTA-DPhe 1-Tyr3-octreotide. Eur J Nucl Med. 2001;28:426-34.
23. Paganelli G, Bodei L, Junak DH, Rocca P, Papi S, Sierra ML, et al. 90Y-DOTA-D-Phe1-Tyr3-octreotide in therapy of neuroendocrine malignancies. Biopolymers (Peptide Science). 2002; 66:393-8.
24. Chinol M, Bodei L, Cremonesi M, Paganelli G. Receptor-mediated radiotherapy with 90Y-DOTA-Dphe1-Tyr3- octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med. 2002;32:141-7. (Pubitemid 34311080)
25. Valkema R, Jamar F, Bakker WH, Norenberg J, Smith C, Stolz B, et al. Safety and efficacy of [Y-90-DOTA, Tyr(3)]octreotide (Y-90-SMT487;OCTREOTHERTM) peptide receptor radionuclide therapy (PRRT): preliminary results of a phase-I study (abstract OS-248). Eur J Nucl Med. 2001;28(Suppl):1025P.
26. Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, et al. Receptor-mediated radionuclide therapy with 90YDOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med. 2003;30:207-16. (Pubitemid 36686839)
27. Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, et al. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3- Octreotide (90Y-DOTATOC] in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2004;31:1038-46. (Pubitemid 38915663)
28. Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0 Tyr3] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36:147-56. (Pubitemid 43320450)
29. Frilling A, Weber F, Saner F, Bockisch A, Hofmann M, Mueller- Brand J, et al. Treatment with 90Y- and 177Lu-DOTATOC in patients with metastatic neuroendocrine tumors. J Surg. 2006; 140(6):968-77. (Pubitemid 44937386)
30. Forrer F, Waldherr C, Maecke HR, Mueller-Brand J. Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res. 2006;26:703-8.
31. Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging. 2008;52:334-40.
32. Muros MA, Varsavsky M, Rozas PI, Valdivia J, Delgado JR, Forrer F, et al. Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Clin Transl Oncol. 2009;11:48-53.
33. De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman APW, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002;32:133-40. (Pubitemid 34311079)
34. Konijnenberg MW. Is the renal dosimetry for [90Y-DOTA 0, Tyr3] octreotide accurate enough to predict thresholds for individual patients? Cancer Biother Radiopharm. 2003;18(4):619-25. (Pubitemid 37082383)
35. Forrer F, Mueller-Brand J, Maecke H. Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2005;32:511-2.
36. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005;46:99S-106S. (Pubitemid 47619025)
37. Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847-56 (epub 22 Apr 2008; erratum in Eur J Nucl Med Mol Imaging. 2008;35:1928).
38. Stolz B, Weckbecker G, Smith-Jones PM, Albert R, Raulf F, Bruns C. The somatostatin receptor-targeted radiotherapeutic [90Y]-DOTA-D-Phel-Tyr3- octeotide([90Y]-SMT487) eradicates experimental rat pancreatic CA 20948 tumors. Eur J Nucl Med. 1998;25:668-74. (Pubitemid 28377028)
39. Gotthardt M, Dijkgraaf I, Boerman OC, Oyen WJG. Nuclear Medicine imaging and therapy of neuroendocrine tumors. Cancer Imaging. 2006;6:S178-84.
40. Pless M, Waldherr C, Maecke H, Buitrago C, Herrmann R, Mueller-Brand J. Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labeled somatostatin analogue: a pilot trial. Lung Cancer. 2004;45:365-71. (Pubitemid 39037718)
41. Iten F, Müller B, Schindler C, Rochlitz C, Oertli D, Mäcke HR, et al. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res. 2007;13:6696-702. (Pubitemid 350206806)
42. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med. 2006;47:1467-75. (Pubitemid 47544933)
43. Smith MC, Liu J, Chen T, Schran H, Yeh CM, Jamar F, et al. OctreoTher: ongoing early clinical development of a somatostatin- receptor-targeted radionuclide antineoplastic therapy. Digestion. 2000;62((Suppl 1)):69-72. (Pubitemid 30665942)
44. Cybulla M, Weiner SM, Otte A. End-stage renal disease after treatment with 90Y-DOTATOC. Eur J Nucl Med. 2001; 28:1552-4.
45. Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)- octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med. 2005;46:83S-91S. (Pubitemid 47619023)
46. Heute D, Kostron H, Guggenberg EV, Ingorokva S, Gabriel M, Dobrozemsky G, et al. Response of recurrent high-grade glioma to treatment with 90Y-DOTATOC. J Nucl Med. 2010; 51:397-400.
47. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273-82. (Pubitemid 30167697)
48. Kwekkeboom DJ, Bakker WH, Kooj PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTA0, Tyr3] octreotate: comparison with [111In-DTPAo] octreotide in patients. Eur J Nucl Med. 2001;28:1319-25.